Glucose Health, Inc. cash flow statement GLUC

Annual Quarterly

In fiscal 2016, which ended Dec 31, 2016, Glucose Health, Inc. used $39,263 of cash from operations, up 66.1% from the year before.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line	FY 2017 Sep 30, 2017	FY 2016 Dec 31, 2016	FY 2015 Dec 31, 2015	FY 2014 Dec 31, 2014	FY 2013 Dec 31, 2013	FY 2012 Dec 31, 2012	FY 2011 Dec 31, 2011
Operating
Stock-based compensation	—	0	—	—	—	—	—
Operating cash flow	-0 +61.8%	-0 +66.1%	-0 +14.5%	-0 -2.6%	-0 -57.7%	-0 -259.2%	-0
Investing
Investing cash flow	—	0 +200.0%	-0	—	—	—	—
Financing
Financing cash flow	0 -83.3%	0 -49.2%	0 -18.9%	0 +6.0%	0 +67.5%	0 +278.4%	0
Change in cash
Effect of exchange rate	—	—	—	—	—	0 +136.0%	0

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as: GLUC (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Bentonville, AR
SEC filer status: Smaller reporting company
SEC CIK: 1420108
Former names: Bio-Solutions Corp. (until Dec 16, 2014)

Other Medicinal Chemicals & Botanical Products companies

All 43 Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.